BioNTech SE stock analysis
BioNTech SE (22UA) Stock Price & Analysis
22UA Stock Chart & Stats
- Day’s Range
- CHF 71.66 - CHF 71.97
- 52-Week Range
- CHF 69.98 - CHF 96.14
- Previous Close
- CHF 70.65
- Volume
- N/A
- Average Volume (3M)
- 29
- Market Cap
- CHF 17.85B
- Enterprise Value
- CHF 9.59B
- Total Cash (Recent Filing)
- CHF 10.20B
- Total Debt (Recent Filing)
- CHF 359.80M
- Price to Earnings (P/E)
- ―
- Beta
- 0.60
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -1.55
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength
BioNTech’s substantial liquidity and very low leverage provide durable flexibility to fund late-stage trials, pursue partnerships, absorb development setbacks, and sustain operations while revenues transition beyond COVID-19 products. This reduces financing pressure during a costly commercialization buildout.
Late-Stage Oncology Pipeline
A broad late-stage pipeline across multiple tumor types gives BioNTech several potential routes to diversify beyond COVID-19 revenue. Multiple pivotal programs and combination strategies can spread clinical risk and create a foundation for a multi-product business over time.
Strategic Partnerships
Partnerships with companies such as Gilead, BMS and Genentech expand BioNTech’s access to complementary assets, clinical capabilities and commercialization resources. The strategy can accelerate combination development while sharing costs and risk across potentially valuable oncology programs.
Bears Say
Structural Revenue Decline
The sharp retreat from pandemic-era revenue reflects BioNTech’s continuing dependence on COVID-19 demand and the difficult transition toward oncology products. Lower recurring revenue reduces operating leverage and makes future profitability more dependent on successful launches or partnership milestones.
Losses And Cash-Flow Pressure
Negative recent cash generation alongside sustained operating losses indicates that BioNTech is consuming financial resources while investing heavily in its pipeline. Although liquidity is strong, prolonged spending without product approvals could reduce flexibility and delay a return to durable profitability.
Clinical Execution Risk
Recent setbacks across several programs show that BioNTech’s pipeline remains exposed to clinical efficacy, safety and development risks. These outcomes can redirect capital, delay product launches and make the company’s planned shift to a diversified multi-product model less certain.
22UA FAQ
What was BioNTech SE’s price range in the past 12 months?
What is BioNTech SE’s market cap?
When is BioNTech SE’s upcoming earnings report date?
How were BioNTech SE’s earnings last quarter?
Is BioNTech SE overvalued?
Does BioNTech SE pay dividends?
What is BioNTech SE’s EPS estimate?
How many shares outstanding does BioNTech SE have?
What happened to BioNTech SE’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioNTech SE?
What is the TipRanks Smart Score and how is it calculated?
BioNTech SE Stock Smart Score
Company Description
BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin
- Employees
- 7,807
- Website
- www.biontech.com/de/de/home.html
- Address
- An der Goldgrube 12, Mainz, RP, 55131, DE
BioNTech SE (22UA) Earnings & Revenues
22UA Company Deck
22UA Earnings Call
Earnings Call SentimentPositive
The call was broadly optimistic, supported by strong gotistobart survival data, encouraging pumitamig combination results, a growing late-stage pipeline, a substantial cash balance, and a raised revenue-guidance midpoint. However, the company also reported lower COVID-19-related revenue, higher R&D and SG&A expenses, discontinuation of the colorectal cancer trial, a missed progression-free survival endpoint for BNT113, and limitations and safety concerns around T-Pam. The highlights significantly outweighed the lowlights, although several clinical programs remain subject to upcoming readouts and development decisions.
View all CH:22UA earnings summaries22UA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 13 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 10 |
